PulseSight Completes Phase I Dosing of PST-611 in Dry AMD
Paris, France | January 22, 2026 — PulseSight Therapeutics, a Paris-based clinical-stage biotechnology company, has announced the successful completion...
Ophthalmology
Advertisement
FDA Approves U.S. Trial for EndoArt Synthetic Corneal Implant
NES ZIONA, Israel, December 8, 2025 — EyeYon Medical Ltd. announced that the U.S. Food and Drug Administration (FDA)...
Kiora Secures New U.S. Patent Expanding KIO-104 Formulation Options
Encinitas, California — December 1, 2025 — Kiora Pharmaceuticals has been granted a new U.S. patent (US-12,472,263) covering additional...
Waseda Study: VR Headsets May Enhance Tear Film Stability
Tokyo, Japan – November 12, 2025 — Waseda University researchers disclosed results from the world’s first time-course observation of...
Kiora Pharmaceuticals Advances Dual Phase 2 Retinal Trials with FDA-Backed Innovation
Dateline — Encinitas, California, November 8, 2024:Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) announced its third-quarter 2024 results alongside significant progress...
Advertisements
Oculis Highlights Late-Stage Eye Pipeline at AAO 2025
October 14, 2025 | Zug, Switzerland — Oculis Holding AG (Nasdaq: OCS), a global biopharmaceutical company advancing therapies for...
Celltrion Secures FDA Approval for EYDENZELT® in Multiple Retinal Diseases
INCHEON, South Korea, Oct. 9, 2025 — Celltrion, Inc., a global biopharmaceutical innovator, announced that the U.S. Food and...
Kodiak’s KSI-101 Delivers Promising Data in Retinal Disease Study
PALO ALTO, Calif., Sept. 15, 2025 – Kodiak Sciences Inc. (Nasdaq: KOD), a retina-focused biotechnology company, announced new data...
Advertisement
